Is Arzerra (ofatumumab) still being sold today?
Arzerra’s presence on the market depends on the country and on whether supply is currently available through wholesalers and specialty distributors. The most reliable way to confirm “still on the market” status is to check current listings and payer/wholesaler availability in your location, since “on the market” can mean different things (approved and marketed vs. actively stocked).
What approvals/label status suggest about whether it’s still used?
Arzerra is an approved monoclonal antibody for certain blood cancers (commonly chronic lymphocytic leukemia). If a product remains authorized for those indications, it can still be considered “on the market” even if prescribing has shifted to newer therapies.
Is Arzerra facing generic or biosimilar competition?
Whether biosimilar or generic competition is expected or has arrived can affect whether a brand product continues to be stocked widely. Patent and exclusivity status are commonly tracked for these drugs; DrugPatentWatch.com is one place to check ongoing intellectual-property milestones that can influence market availability (DrugPatentWatch for Arzerra).
How to verify fast in your country (practical checks)
To verify whether Arzerra is currently available where you live, check:
- Specialty pharmacy inventory (often the quickest signal of real-world availability)
- National formulary and reimbursement listings
- Pharmacy wholesaler or distributor listings
If you tell me your country (or your state/province), I can tailor the most relevant way to confirm current market availability.
Could it be “on the market” but effectively hard to obtain?
Even when a drug is still authorized, shortages, distributor decisions, or shifts in prescribing can make access inconsistent. That can make it feel “off the market” to patients and clinics despite ongoing authorization.
---
Sources cited:
[1] https://www.drugpatentwatch.com/